keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer side effects

keyword
https://www.readbyqxmd.com/read/28340378/current-fda-approved-treatments-for-non-small-cell-lung-cancer-and-potential-biomarkers-for-its-detection
#1
REVIEW
Karla A Ruiz-Ceja, Yolanda I Chirino
BACKGROUND: Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? AIM: In this review we analyzed how the approved drugs by Federal Drug Agency for NSCLC have advanced in the last four decades identifying shared mechanism of action of medicines against NSCLC treatment and some of the potential biomarkers for early detection...
March 21, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28337370/role-of-epidermal-growth-factor-receptor-in-lung-cancer-and-targeted-therapies
#2
REVIEW
Tie-Cheng Liu, Xin Jin, Yan Wang, Ke Wang
Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers (SCLC), have responded effectively to chemo-, radiation and adjuvant-therapies. Tumor removal through surgery also appeared as a good therapeutic strategy. However, these therapies demonstrated unfavourable side-effects, and hence novel drugs targeting lung cancer emerged essential. Activation of epidermal growth factor receptor (EGFR)-tyrosine kinases is a key reason for lung cancer progression...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28303311/-immunotherapy-of-cancer-with-checkpoint-inhibitors-not-only-in-malignant-melanoma
#3
A Neubauer
The newest weapon in cancer therapy is checkpoint inhibition, which is the result of basic immunology research. The success of this therapy is based on the fact that upon light microscopy, many solid tumors harbor lymphocytic cells infiltrating the tumor (TILs), and in many solid tumors, the presence of these TILs are prognostic. Ipilimumab was the first monoclonal antibody developed against a target present on T cells after becoming activated, CTLA-4. In malignant melanoma, ipilimumab showed its beneficial effect as compared to a placebo peptide...
March 16, 2017: Der Internist
https://www.readbyqxmd.com/read/28302224/-advances-in-the-research-of-the-regulation-of-chinese-traditional-medicine-monomer-and-its-derivatives-on-autophagy-in-non-small-cell-lung-cancer
#4
Meiyi Xiang, Ruilei Li, Zhiwei Zhang, Xin Song
The high morbidity and mortality of non-small cell lung cancer (NSCLC) did influence the quality of life of tumor patients world-wide. There is an urgent need to develop new therapies that have high anti-tumor activity and low toxicity side effects. It is widely accepted that autophagy can play diverse roles in carcinogenesis, such as induces pro-death of lung cancer cells or helps the escape from cell death, making it become a proper anticancer target. It's believed that various monomers of Chinese traditional medicine closely correlates to anti-NSCLC activities, and that even could affect the acquired multiple drug resistance (MDR)...
March 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28297341/assessment-of-monte-carlo-algorithm-for-compliance-with-rtog-0915-dosimetric-criteria-in-peripheral-lung-cancer-patients-treated-with-stereotactic-body-radiotherapy
#5
Damodar Pokhrel, Sumit Sood, Rajeev Badkul, Hongyu Jiang, Christopher McClinton, Christopher Lominska, Parvesh Kumar, Fen Wang
The purpose of the study was to evaluate Monte Carlo-generated dose distributions with the X-ray Voxel Monte Carlo (XVMC) algorithm in the treatment of peripheral lung cancer patients using stereotactic body radiotherapy (SBRT) with non-protocol dose-volume normalization and to assess plan outcomes utilizing RTOG 0915 dosimetric compliance criteria. The Radiation Therapy Oncology Group (RTOG) protocols for non-small cell lung cancer (NSCLC) currently require radiation dose to be calculated using tissue density heterogeneity corrections...
May 2016: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28273195/-role-of-pembrolizumab-in-the-treatment-of-non-small-cell-lung-cancer-nsclc
#6
Gabriella Gálffy, Rita Puskás
Lung cancer is the leading cause of cancer-related death, not only in our country but also worldwide. It is particularly the incidence and mortality regarding females that have increased significantly in recent years. For many years chemotherapeutic treatments of lung cancer were the only way forward in the treatment of patients. In 2015 immunotherapy proved to be a great breakthrough in the treatment of non-small cell lung cancer (NSCLC), resulting from a new treatment strategy, described as immune checkpoint inhibition...
March 8, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28254730/management-of-brain-metastasized-non-small-cell-lung-cancer-nsclc-from-local-treatment-to-new-systemic-therapies
#7
REVIEW
G Tsakonas, L De Petris, S Ekman
Lung cancer has the highest frequency of brain dissemination compared to all other solid tumours. Classical treatment options such as brain irradiation have started to be questioned due to lack of survival benefit and risk for severe side effects. Oncogenic driven tumours have the highest frequency of brain dissemination among NSCLC patients and available targeted therapies have shown activity both intra-and extracranially, with an acceptable toxicity profile. The recent approval of immune checkpoint inhibitors for the treatment of NSCLC has complicated treatment selection even more...
March 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28243683/effect-of-alectinib-on-cardiac-electrophysiology-results-from-intensive-electrocardiogram-monitoring-from-the-pivotal-phase-ii-np28761-and-np28673-studies
#8
Peter N Morcos, Katrijn Bogman, Stanislas Hubeaux, Carolina Sturm-Pellanda, Thorsten Ruf, Walter Bordogna, Sophie Golding, Ali Zeaiter, Markus Abt, Bogdana Balas
PURPOSE: Alectinib, a central nervous system (CNS)-active ALK inhibitor, has demonstrated efficacy and safety in ALK+ non-small-cell lung cancer that has progressed following crizotinib treatment. Other ALK inhibitors have shown concentration-dependent QTc prolongation and treatment-related bradycardia. Therefore, this analysis evaluated alectinib safety in terms of electrophysiologic parameters. METHODS: Intensive triplicate centrally read electrocardiogram (ECG) and matched pharmacokinetic data were collected across two alectinib single-arm trials...
February 27, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28239469/combination-immunotherapy-a-road-map
#9
REVIEW
Patrick A Ott, F Stephen Hodi, Howard L Kaufman, Jon M Wigginton, Jedd D Wolchok
Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28228221/-efficacy-and-potential-application-of-neoadjuvant-chemotherapy-in-patients-with-iiia-stage-non-small-cell-lung-cancer
#10
Cuiping Tang, Si Qin, Wanchun Wu, Yang Wu, Tao Zhang
BACKGROUND: The therapeutic effect and side effect of neoadjuvant chemotherapy were still disputing issues when applied to resectable IIIa stage non-small cell lung cancer (NSCLC) patients. The retrospective analysis was aimed to investigate the short-term efficacy and postoperative complications in resectable IIIa NSCLC patients treated with neoadjuvant chemotherapy. METHODS: According to inclusion criteria and exclusion criteria, 370 patients with clinical diagnosis of IIIa NSCLC were selected from our hospital between January 2011 and October 2013 were retrospectively analyzed...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28209994/reversal-of-the-apoptotic-resistance-of-non-small-cell-lung-carcinoma-towards-trail-by-natural-product-toosendanin
#11
Xin Li, Ming You, Yong-Jian Liu, Lin Ma, Pei-Pei Jin, Ri Zhou, Zhao-Xin Zhang, Baojin Hua, Xiao-Jun Ji, Xiao-Ying Cheng, Fangzhou Yin, Yan Chen, Wu Yin
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively triggers cancer cell death via its association with death receptors on the cell membrane, but exerts negligible side effects on normal cells. However, some non-small-cell lung carcinoma (NSCLC) patients exhibited resistance to TRAIL treatment in clinical trials, and the mechanism varies. In this study, we described for the first time that toosendanin (TSN), a triterpenoid derivative used in Chinese medicine for pain management, could significantly sensitize human primary NSCLC cells or NSCLC cell lines to TRAIL-mediated apoptosis both in vitro and in vivo, while showing low toxicity against human primary cells or tissues...
February 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28209203/crizotinib-associated-renal-cysts-carcs-incidence-and-patterns-of-evolution
#12
Laird B Cameron, Damian H S Jiang, Kate Moodie, Catherine Mitchell, Benjamin Solomon, Bimal Kumar Parameswaran
BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature...
February 16, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/28161551/antitumoral-effect-and-reduced-systemic-toxicity-in-mice-after-intra-tumoral-injection-of-an-in-vivo-solidifying-calcium-sulfate-formulation-with-docetaxel
#13
Stefan Grudén, Martin Sandelin, Veera Rasanen, Patrick Micke, Mikael Hedeland, Niklas Axén, Marie Jeansson
BACKGROUND: Docetaxel is a cytostatic agent approved for treatment of non-small cell lung cancer as well as other cancers. Although docetaxel is an effective cytostatic agent, its effectiveness in clinical practice is associated with a variety of acute and long term side-effects. To overcome systemic side effects, a slow release formulation based on calcium sulfate with docetaxel for intra-tumoral administration was developed. METHODS: Two formulations with the calcium sulfate NanoZolid technology were generated with a twofold difference in docetaxel drug load...
February 1, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28150074/a-phase-ii-study-of-carboplatin-plus-weekly-paclitaxel-with-bevacizumab-for-elderly-patients-with-non-squamous-non-small-cell-lung-cancer-nej016
#14
Satoru Miura, Makoto Maemondo, Akira Iwashima, Toshiyuki Harada, Shunichi Sugawara, Kunihiko Kobayashi, Akira Inoue, Taku Nakagawa, Yuichi Takiguchi, Hiroshi Watanabe, Takashi Ishida, Masaki Terada, Hiroshi Kagamu, Akihiko Gemma, Hirohisa Yoshizawa
Background The efficacy and safety of bevacizumab in elderly patients with non-small cell lung cancer remain controversial. This study focused on both selecting fit elderly patients and overcoming interpatient variability with respect to pharmacodynamics. Methods Elderly (age: ≥70 years) patients with advanced non-squamous non-small cell lung cancer were enrolled. Patients with uncontrolled congestive heart failure and uncontrolled diabetes were excluded. The treatment regimen comprised carboplatin at an area under the curve of 5 mg/ml/min on day 1, paclitaxel at 90 mg/m(2) on days 1 and 8, and bevacizumab at 15 mg/kg on day 1 every 21 days for up to 4 cycles, followed by maintenance bevacizumab...
April 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28123519/role-of-gambogic-acid-and-nai-131-in-a549-ddp-cells
#15
Jing Huang, Xiaoli Zhu, Huan Wang, Shuhua Han, Lu Liu, Yan Xie, Daozhen Chen, Qiang Zhang, Li Zhang, Yue Hu
Resistance to platinum in tumor tissue is a considerable barrier against effective lung cancer treatment. Radionuclide therapy is the primary adjuvant treatment, however, the toxic side effects limit its dosage in the clinical setting. Therefore, the present study aimed to determine whether an NaI(131) radiosensitizer could help reduce the toxic side effects of radionuclide therapy. In vitro experiments were conducted to determine whether NaI(131) can inhibit platinum resistance in A549/DDP cells, which are cisplatin-resistant non-small cell lung cancer cells, and whether gambogic acid (GA) is an effective NaI(131) radiosensitizer...
January 2017: Oncology Letters
https://www.readbyqxmd.com/read/28119812/inhalable-oridonin-loaded-poly-lactic-co-glycolic-acid-large-porous-microparticles-for-in-situ-treatment-of-primary-non-small-cell-lung-cancer
#16
Lifei Zhu, Miao Li, Xiaoyan Liu, Lina Du, Yiguang Jin
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Traditional chemotherapy for this disease leads to serious side effects. Here we prepared an inhalable oridonin-loaded poly(lactic-co-glycolic)acid (PLGA) large porous microparticle (LPMP) for in situ treatment of NSCLC with the emulsion/solvent evaporation/freeze-drying method. The LPMPs were smooth spheres with many internal pores. Despite a geometric diameter of ~10 µm, the aerodynamic diameter of the spheres was only 2.72 µm, leading to highly efficient lung deposition...
January 2017: Acta Pharmaceutica Sinica. B
https://www.readbyqxmd.com/read/28117614/measurement-of-health-related-quality-of-life-during-chemotherapy-the-importance-of-timing
#17
Are Kristensen, Tora S Solheim, Tore Amundsen, Harald H Hjelde, Stein Kaasa, Sveinung Sørhaug, Bjørn H Grønberg
BACKGROUND: Side effects of chemotherapy may occur at different time-points in the treatment cycle, and the exact assessment time relative to chemotherapy may affect HRQoL scores. The current study examined the variation of HRQoL during chemotherapy cycles, and whether differences in HRQoL scores varied at selected time-points between patients allocated to two different chemotherapy regimens. MATERIAL AND METHODS: Patients with stage IIIB or IV non-small-cell lung cancer (NSCLC) were randomly assigned to receive three cycles of carboplatin plus vinorelbine (VC) or gemcitabine (GC) every 3 weeks...
January 24, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28068937/the-efficacy-and-roles-of-combining-temozolomide-with-whole-brain-radiotherapy-in-protection-neurocognitive-function-and-improvement-quality-of-life-of-non-small-cell-lung-cancer-patients-with-brain-metastases
#18
Xia Deng, Zhen Zheng, Baochai Lin, Huafang Su, Hanbin Chen, Shaoran Fei, Zhenghua Fei, Lihao Zhao, Xiance Jin, Cong-Ying Xie
BACKGROUND: Brain metastasis (BM) is a poor prognostic factor for non-small-cell lung cancer (NSCLC). The efficacy and roles of combining temozolomide (TMZ) with whole brain radiotherapy (WBRT) in protection neurocognitive function (NCF) and improvement quality of life (QOL) were investigated and compared with WBRT alone in the treatment of NSCLC patients with BM. METHODS: A total of 238 NSCLC patients with BM were reviewed and categorized into WBRT plus TMZ (RCT) arm and WBRT alone (RT), respectively...
January 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28048395/we-fg-206-07-assessing-the-lung-function-of-patients-with-non-small-cell-lung-cancer-using-hyperpolarized-xenon-129-dissolved-phase-mri
#19
K Qing, J Mugler, Q Chen
PURPOSE: Hyperpolarized xenon-129 dissolved-phase MRI is the first imaging technique that allows 3-dimensional regional mapping of ventilation and gas uptake by tissue and blood the in human lung. Multiple outcome measures can be produced from this method. Existing studies in subjects with major lung diseases compared to healthy controls demonstrated high sensitivities of this method to pulmonary physiological factors including ventilation, alveolar tissue density, surface-to-volume ratio, pulmonary perfusion and gas-blood barrier thickness...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28045490/an-allosteric-inhibitor-scaffold-targeting-the-pif-pocket-of-atypical-protein-kinase-c-isoforms
#20
Jose M Arencibia, Wolfgang Fröhner, Magdalena Krupa, Daniel Pastor-Flores, Piotr Merker, Thomas Oellerich, Sonja Neimanis, Christian Schmithals, Verena Köberle, Evelyn Süß, Stefan Zeuzem, Holger Stark, Albrecht Piiper, Dalibor Odadzic, Jörg O Schulze, Ricardo M Biondi
There is a current and pressing need for improved cancer therapies. The use of small molecule kinase inhibitors and their application in combinatorial regimens represent an approach to personalized targeted cancer therapy. A number of AGC kinases, including atypical Protein Kinase C enzymes (PKCs), are validated drug targets for cancer treatment. Most drug development programs for protein kinases focus on the development of drugs that bind at the ATP-binding site. Alternatively, allosteric drugs have great potential for the development of future innovative drugs...
January 13, 2017: ACS Chemical Biology
keyword
keyword
3577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"